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Illicit methadone injecting during methadone maintenance
treatment in a specialised out-patient clinic
Abstract
AIM: The injection of non-sterile methadone designed for oral consumption is associated with
serious health risks. There is only a small number of studies on this topic, with divergent
results. The main aim of the present study was to obtain data on the frequency of methadone
injecting in a state out-patient clinic specialised in substance use disorders. METHODS: Eighty
patients in methadone maintenance treatment were interviewed with a short questionnaire.
Mean age was 32 years, 76% were male, mean methadone dose was 55 mg. RESULTS:
Twenty-six patients (32%) indicated having injected methadone at least once in their life. Only
four patients (5%) reported having injected methadone within the preceding month (mean
dose 56 mg). All four had injected additional substances during this month. CONCLUSIONS:
Frequency rates appeared low compared with other studies despite a generous take-away
policy. The results suggest an association between methadone injecting and a more general
tendency to inject substances.
Illicit methadone injecting
during methadone maintenance treatment 
in a specialised out-patient clinic 
Doris Waldvogel, Bernd Figner, Dominique Eich
Psychiatric University Clinic, Zurich
Aim: The injection of non-sterile methadone
designed for oral consumption is associated with
serious health risks. There is only a small number
of studies on this topic, with divergent results. The
main aim of the present study was to obtain data
on the frequency of methadone injecting in a state
out-patient clinic specialised in substance use dis-
orders. 
Methods: Eighty patients in methadone main-
tenance treatment were interviewed with a short
questionnaire. Mean age was 32 years, 76% were
male, mean methadone dose was 55 mg.
Results: Twenty-six patients (32%) indicated
having injected methadone at least once in their
life. Only four patients (5%) reported having in-
jected methadone within the preceding month
(mean dose 56 mg). All four had injected additional
substances during this month. 
Conclusions: Frequency rates appeared low
compared with other studies despite a generous
take-away policy. The results suggest an associa-
tion between methadone injecting and a more gen-
eral tendency to inject substances. 
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Methadone maintenance treatments (MMTs)
are nowadays widely recognised as an efficient
strategy in the treatment of opiate dependence.
One of the problems of MMTs is the injection of
take-away methadone doses intended for oral con-
sumption. The injection of non-sterile methadone
mixed with syrup poses serious health risks such 
as venous damage and systemic infections [1].
Most of the information about the frequency
of this behaviour originates from Australia (see
table 1). As can be seen from the table, the studies
presented have similar samples with respect to age,
percentage of males and methadone dose. The
samples differ, however, with respect to number 
of subjects in MMT, number of subjects who in-
ject heroin, and substitution with peroral or in-
jectable methadone. The results are divergent: be-
tween 18 and 52% of the subjects indicated having
injected methadone at least once in their life, be-
tween 1.2 and 31% at least once within the past six
months, and between 20 and 41% at least once
during the last month. As it seems difficult to ex-
plain these differences, it was the main aim of the
present study to gather additional data on the fre-
quency of methadone injections.
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Introduction
Setting: The present study was conducted in a clinic
in Zurich, Switzerland. The clinic is an out-patient depart-
ment of the psychiatric university clinic, located in a quiet
residential area. The staff consists of psychiatrists, general
practitioners, psychologists, nurses, social workers, and
administration personnel. The clinic offers psychiatric
treatment for persons who are or were dependent on ille-
gal drugs and accepts every person who seeks this sort of
help. Treatment strategies include a long-term perspec-
tive; improvement of psychological and physical health
and social integration are seen as more important than ab-
stinence from drugs. Patients in MMT obtain between
two and seven take-away doses per week, regardless of the
time they have spent in methadone maintenance, but 
depending on the reliability of the individual patient. 
Procedure: The interviewers obtained a list of all 
patients who were in methadone maintenance for at least
one month. Patients who obtained methadone for less
than 30 days as well as patients who obtained other or no
medication were not considered. Interviewers were two
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interns (psychology and social work students). They ap-
proached the patients individually at the counter or in the
waiting room and asked each one to participate in the
study. If the patient agreed, the interview was conducted
in the waiting room; interviewer and patient were alone
during this time. Participation was voluntary and anony-
mous. All participants signed an informed consent. The
study was approved by the Psychiatric University Clinic’s
Ethics Committee.
The questionnaire contained the following questions:
– Concerning lifetime: did you ever inject methadone;
at what age for the first time; which was the first sub-
stance you ever injected?
– Concerning the preceding month: did you inject
methadone; how many doses of methadone were you
allowed to take away; of these, how many doses 
did you inject; did you inject other substances; if so
which ones?
– Age, dosage of methadone, and age at the beginning
of heroin dependence. Information about the dura-
tion of MMT was gathered from hospital records.
Sample: Of the 87 patients who were methadone-
maintained for at least one month, 80 patients (92%) were
interviewed; three persons refused and four persons
stopped their treatment. The recruitment period had a du-
ration of 21 days. 
The sample (n = 80) had the following characteristics:
mean age 32 years (SD = 6.0, range 16–48); 76% males;
mean methadone dose 55 mg (SD = 27, range 5–150);
mean duration of methadone maintenance 17 months 
(SD = 15, range 1–72); mean age at the beginning of opi-
ate dependence 21 years (SD = 4.9, range 11–32).
Lifetime: Twenty-six patients (32%) indicated
having injected methadone at least once in their
life (mean age 33 years, SD = 5.3; mean dosage of
methadone 52 mg, SD = 23; mean duration 
of methadone maintenance 21 months, SD = 18;
mean age at the beginning of opiate dependence
21 years, SD = 4.5). Regarding sample character-
istics they did not differ substantially from the
other 54 patients. Mean age at the first injection of
methadone was 25 years (SD = 5.7). None of the
patients reported that methadone was the first sub-
stance he or she had ever injected. All of the 26 
patients who had injected methadone had also 
injected heroin in the past; of the other 54 patients
only 36 (67%) had injected heroin in the past. 
Patients who had injected heroin had a 1.5 times
higher probability of having also injected metha-
done (unadjusted risk ratio 1.5, 95% CI 1.2–1.8,
CI calculated using the delta method).
Preceding month: Four patients or 5% of the
sample (n = 80) indicated having injected
methadone during the preceding month, three 
of them occasionally (up to three doses of 20, 24
and 30 take-away doses), and one of them regu-
larly (seven of eight take-away doses). All of 
these four patients had injected other substances
(heroin, cocaine, flunitrazepam) in the preceding
month.
Results
The rate of past methadone injecting proved
to be 32% in this sample with a mean age of 32
years. This is a “medium” rate compared with 52%
[2], 42% [3] and 18% [4], with a mean age of 
29 years in these three samples. Likewise, the 
frequency of injecting methadone at present ap-
peared to be low, as only 5% of the patients indi-
cated having injected methadone during the past
month, compared to 21% [3]. All patients who had
injected methadone had also injected heroin in the
past, of the other patients only 67%. The four pa-
tients who had injected methadone during the pre-
ceding month had also injected other substances
during this time.  
Discussion
Table 1
Results of studies 
on illicit methadone
injecting.
Authors Sample Mean age Mean methadone Illicit injection of methadone
lifetime at present
Lintzeris et al. 1999, 168 patients in methadone 34 years – – 1.2%
Melbourne, AUS [1] substitution 59% male last 6 months
Darke et al. 1996, 312 heroin injecting 29 years – 52% 29%
Sydney, AUS [2] subjects 61% male last 6 months
of these 166 in methadone – 64 mg 50% 31%
substitution last 6 months
Humeniuk et al. 2003, 365 heroin users (of these 86 29 years 53 mg 18% 11%
Adelaide, AUS [4] in methadone substitution) 59% male last 6 months
Waldvogel & 134 patients in methadone 29 years – 42% 21%
Uehlinger 1999, substitution of these 80% male last month
Fribourg, CH [3]
107 with peroral methadone – – – 20%
last month
17 with injectable methadone – – – 41%
last month
Present study, Zurich, CH 80 patients in 32 years 55 mg 32% 5%
methadone substitution 76% male last month
Place % of males dose
The present study has some limitations. First,
information on methadone injecting was self-
reported. Patients may have under-reported the
frequency of methadone injecting, although the
consumption of drugs (including the injection 
of methadone) does not have negative conse-
quences for the patients’ treatment and the ques-
tionnaires were carried out anonymously by in-
terns. A second limitation is the issue of represen-
tativeness of the sample and generalizability of the
findings. Although the participation rate was high
(92%), the sample (n = 80) was small, which affects
its representativeness for other methadone-main-
tained patients.
Lintzeris et al. [1] proposed different take-
away policies as an explanation for differences 
in prevalence rates, as higher availability of
methadone take-aways increases the capacity for
inappropriate use. This hypothesis is not sup-
ported by the present results, as the frequency of
current methadone injecting was low, despite the
opportunity to take away two to seven doses per
week. The association between past methadone in-
jecting and past heroin injections found in the
present study is consistent with Humeniuk et al.
[4]. They found that those who inject methadone
were significantly more likely to use other drug
types intravenously than those who did not, never
or not within the last six months. Further research
will have to show whether the habit to inject heroin
and other substances is a major predictor for in-
jecting prescribed methadone.
Several conclusions might be stated: First, 
frequency rates regarding methadone injecting are
heterogeneous, not only in Australia, but also in
Switzerland. This implies that the findings regard-
ing the frequency of methadone injecting of this
study cannot be extrapolated towards other treat-
ment centres specialised in opiate addiction. More
studies on this topic are needed. Second, patients
who injected heroin and other substances in the
past should obtain special attention regarding
methadone injecting. And third, a generous take-
away policy does not necessarily lead to a higher
rate of methadone injecting. 
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